Biomedical catalyst 2017 round 3: feasibility studies

Key Features

Micro, small or medium-size UK companies can apply for a share of £2 million to work alone or with others on solving healthcare challenges.

Programme:     Innovate UK

Award:     Up to £140k

Opens: 31st Jul 2017

Closes: 11th Oct 2017

! This scheme is now closed

The aim of this competition is to support the development of innovative healthcare technologies and processes. These may include:

  • disease prevention and proactive management of health and chronic conditions
  • earlier and better detection and diagnosis of disease, leading to better patient outcomes
  • tailored treatments that either change the underlying disease or offer potential cures

The biomedical catalyst has 4 types of funding award designed to support small to medium enterprises (SMEs) that are developing a product or process. It helps them progress from initial concept through to late-stage development.

Each type of award has a different scope. You should apply only if your project fits a specific competition scope.

This is a feasibility competition which is looking to fund projects that explore and evaluate the commercial potential of innovative scientific ideas by:

  • reviewing research evidence and identifying possible applications
  • assessing business opportunities
  • investigating the intellectual property position
  • validating initial concepts or existing pre-clinical work through experimental studies
  • identifying areas for further development


You must:

  • be a UK-based SME to lead a project
  • work on your own or with other UK SMEs or research organisations
  • carry out your project work in the UK
  • be ready to start your project by 1 February 2018 and finish by 1 February 2019

Projects are expected to range in size up to £200,000.

Projects should last no longer than 12 months.

Total project costs of up to £200,000.

Your project must focus on technical feasibility studies. You could get up to 70% of your eligible project costs if you are an SME.